Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial

IMPORTANCE: There is an unmet medical need for the treatment of recurrent ovarian cancer, and new approaches are needed to improve progression-free survival (PFS) and overall survival. OBJECTIVE: This phase 1/2 study evaluated the activity of alisertib in combination with weekly paclitaxel in patien...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Oncol
Autori principali: Falchook, Gerald, Coleman, Robert L., Roszak, Andrzej, Behbakht, Kian, Matulonis, Ursula, Ray-Coquard, Isabelle, Sawrycki, Piotr, Duska, Linda R., Tew, William, Ghamande, Sharad, Lesoin, Anne, Schwartz, Peter E., Buscema, Joseph, Fabbro, Michel, Lortholary, Alain, Goff, Barbara, Kurzrock, Razelle, Martin, Lainie P., Gray, Heidi J., Fu, Siqing, Sheldon-Waniga, Emily, Lin, Huamao Mark, Venkatakrishnan, Karthik, Zhou, Xiaofei, Leonard, E. Jane, Schilder, Russell J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2018
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439781/
https://ncbi.nlm.nih.gov/pubmed/30347019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.3773
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi